ClinicalTrials.gg
TerminatedNCT01329809Updated Oct 2, 2026Results posted

Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection

A Phase 2 interventional study of Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594) in Colorectal Carcinoma, sponsored by Jennerex Biotherapeutics. Terminated at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Jennerex Biotherapeutics · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Business decision by the sponsor
Updated Oct 2, 2026Results postedReason for stopping updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 379 studies in Colorectal Neoplasms with a site in Canada — 72 open to participants now, 116 under way, 12 of them phase 3. Colorectal Neoplasms · Canada.

Enrollment
320th of 324
2 · median 151
Started
2011
with 12 others
Phase 2
83 of 379
12 open now
Registered
113th of 379
by date

Among the 379 studies in Colorectal Neoplasms with a site in Canada, this one is the 320th largest by enrollment of the 324 interventional ones that give a count, is one of 13 that started in 2011, is one of 83 in phase 2, and was the 113th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

72 of the 379 studies in Colorectal Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 379 studies in Colorectal Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

This is a neoadjuvant Phase 2a, open-label trial in patients with metastatic colorectal carcinoma who are undergoing a complete resection of the metastatic colorectal tumors in their liver.

Read the detailed description

Patients will receive either an intravenous infusion or an intratumoral injection of JX-594 (Pexa-Vec) directly into one liver lesions at Day 1. Patients will undergo a complete resection of all liver tumors at Day 15. Patients will then be monitored throughout their life for disease recurrence and/or general overall survival.

03

Conditions studied

  • Colorectal Carcinoma

Keywords

  • metastatic colorectal cancer
  • colon cancer
  • liver metastasis
  • Pexa-vec
  • JX-594
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The planned surgical resection must be margin negative with complete resection or resection plus radiofrequency ablation (RFA) of CRC as determined by principal investigator or surgeon
  • Diagnosis of -confirmed metastatic colorectal tumor(s) within the liver eligible for surgical resection. Eligible patients must have: preoperative work-up that reveals potential resectability (CT scan or MRI of the abdomen and pelvis and CT scan of the chest within 6 weeks of enrollment) preoperative work-up to ensure operability with general medical clearance as indicated
  • At least one measurable tumor mass by MRI (i.e. lesion that can accurately be measured in at least one dimension with longest diameter ≥ 1 cm)
  • Plan for a maximum resection of six (6) liver segments
  • A (Refer to APPENDIX C: Child-Pugh Classification
  • Performance Score: score of ≥ 70
  • Age ≥18 years
  • For patients treated with IT injection only: at least 1 intra-hepatic tumor with longest diameter (LD) ≥ 1.5 cm and ≤ 12 cm and which is technically amenable to injection under radiographic guidance targeted for surgical resection.
  • In patients treated with IT injection, the injected tumor must be included in the surgical resection specimen (a planned RFA of the injected tumor would not be eligible)
  • Total ≤ 3 x
  • , ALT \< 5.0 x ULN
  • WBC ≥ 3.5x 109/L and ≤ 50 x 109/L
  • ≥1.5 x 109/L
  • ≥ 200 total cells/mm3
  • ≥ 80g/L
  • count ≥ 100 x 109/L
  • Acceptable coagulation status: ≤ 1.4
  • Creatinine ≤ 2 x ULN
  • Serum Sodium, Potassium and Calcium levels ≤ Grade 1
  • If patients are diabetic or have a screening random glucose > 8.9mmol/L, a fasting glucose must be done and results must be WNL or Grade 1 in order to be eligible for the study.
  • For patients who are sexually active: patient must be able and willing to abstain from sex during JX-594 treatment period (to prevent pregnancy) and willing to use barrier method for at least 6 weeks after the last JX-594 treatment (to protect partner against infection).
  • Able and willing to sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)/Research Ethics Board (REB)-approved written consent form Able and willing to comply with study procedures and follow-up examinations, including compliance with the "Infection Control Guidelines for Patients" contained within the written consent form.

Exclusion criteria

Exclusion Criteria:

  • Prior local-regional treatment (including hepatic arterial infusion, hepatic embolization, radiofrequency ablation) for tumor downstaging. Prior chemotherapy will be accepted as long as the duration between chemotherapy and the development of has been >8 weeks.
  • Pregnant or nursing an infant
  • Known myeloproliferative disorders requiring systemic therapy
  • Significant immunodeficiency due to underlying illness (e.g. /AIDS) and/or medication (e.g. high dose systemic taken for more than 4 weeks within the preceding 3 months)
  • History of severe exfoliative skin condition (e.g. eczema or atopic dermatitis requiring systemic therapy for more than 4 weeks)
  • Tumor(s) invading a major vascular structure (e.g. carotid artery)
  • and/or rapidly accumulating ascites, pericardial and/or pleural effusions
  • Clinically significant active infection, requiring systemic antibiotic therapy, or uncontrolled medical condition which would, in the opinion of the principle investigator, impair the ability of the subject to receive protocol therapy
  • Severe or unstable cardiac disease, including significant coronary artery disease requiring angioplasty or stenting within the preceding 12 months, unless well-controlled and on stable medical therapy for at least 3 months
  • Known viable CNS (history of completely resected or irradiated allowed)
  • Chronic use of anti- or anti-coagulation medication that cannot be temporarily discontinued for at least seven days prior to treatment with JX-594. (Note: the following are allowed: low dose aspirin ≤ 100 mg, low dose coumadin as long as ≤ 1.4 and low-dose heparin to maintain port access)
  • Use of the following anti-viral agents: ribavirin, adefovir, cidofovir (at least 7 days prior to the first treatment), and PEG-IFN (at least 14 days prior to the first treatment).
  • Absolute to undergoing MRI scanning (e.g. pacemaker, paramagnetic intracranial aneurysm clip, inner ear implants, fragments of metal within the body, etc.).
  • Pulse oximetry O2 saturation \< 90% at rest
  • Experienced a severe systemic reaction or side-effect as a result of a previous smallpox vaccination
  • Inability or unwillingness to give or comply with the procedures required in this protocol.
  • Patients with household contacts who meet any of these criteria will be excluded unless alternate living arrangements can be made during the patient's dosing period and for at least 7 days following the last dose of study medication
  • Pregnant or nursing an infant
  • Children \< 1 year old
  • People with skin disease (eczema, atopic dermatitis and related diseases
  • hosts (severe deficiencies in cell-mediated immunity, including AIDS, organ transplant recipients, hematologist malignancies)
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    JX-594 Intravenous infusion

    At Day 1 patients will receive either an intratumoral injection or intravenous infusion. The treatment given is determined by the patient's tumor characteristics. Patients with ≥ 2 qualifying intrahepatic CRC metastases, where at least one (1) tumor measures ≥ 1.5 cm LD and is injectable under radiographic guidance (e.g. ultrasound or CT guidance), will receive an intratumoral injection. Patients with only one (1) qualifying intrahepatic CRC metastasis, or with tumors \< 1.5cm and/or no injectable tumors, will receive an intravenous infusion.

    Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

  • Experimental
    JX-594 Intratumoral Injection

    At Day 1 patients will receive either an intratumoral injection or intravenous infusion. The treatment given is determined by the patient's tumor characteristics. Patients with ≥ 2 qualifying intrahepatic CRC metastases, where at least one (1) tumor measures ≥ 1.5 cm LD and is injectable under radiographic guidance (e.g. ultrasound or CT guidance), will receive an intratumoral injection. Patients with only one (1) qualifying intrahepatic CRC metastasis, or with tumors \< 1.5cm and/or no injectable tumors, will receive an intravenous infusion.

    Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

Interventions

  • DrugJX-594Studies of JX-594JX-594 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion

    Also known as: JX-594

06

What researchers measure

Primary outcomes

  1. Delivery to and Replication Within Tumors

    IT injection: replication and dissemination of JX-594 following injection of a single colorectal metastasis within the liver. A positive replication response is defined as a \> 2-fold increase in viral genome concentration in the blood(as measured in the first 12 hours following injection) within the first 14 days following treatment. Note: Viral genomes will be measured in the blood by Q-PCR at baseline, on Day 1 (15 minutes, 3 hours \& 8 hours) post-treatment and on Days 3, 5, 8, 11 and 15. IV infusion: assessment of viral gene \& protein expression in histologic samples of tumor tissue

    Time frame: Day 1, 3, 5, 8, 11, and 15

Secondary outcomes

  1. JX-594 Spread to, and Replication Within, Non-injected Tumors After IT JX-594 Injection

    JX-594 spread to, and replication within, non-injected tumors after IT JX-594 injection as measured by the presence of viral protein expression and/or LacZ expression in non-injected tumor sections from at least 1) two different non-consecutive cuts, both of which contain viable tumor tissue in at least 10 high power fields; and 2) at least 5 cells in one high power field show positive staining for viral protein and/ or LacZ expression

    Time frame: Day 1

  2. Modified Choi Response Assessment

    Modified Choi response assessment based on DCE-MRI at baseline and between Days 8 14 (within 7 days prior to surgical resection)

    Time frame: Day 8-14

  3. Toxicity: Grade I-IV Adverse Events (According to CTCAE)

    Toxicity: Grade I-IV Adverse Events (according to CTCAE); including surgical complications such as delay of surgery, prolonged hospitalization, bleeding (monitor transfusion requirements), postoperative infections, bile leak, hepatic failure sepsis and death

    Time frame: Day 1- Day 43

07

Results

Posted Oct 2, 2026
Limitations and caveats
This study was initiated in 2011 and prematurely completed in 2013. Also, the investigational product (Pexa-vec) has not been approved in any market as of today. Although the verifiable data are limited, we have faithfully entered all information that was available at the time. However, if deleting this entry/section is deemed more appropriate, please provide guidance on how to proceed.

Participant flow

Due to the early termination of the trial, primary and secondary outcome data were not captured. Only available safety data for the enrolled participants have been reported in the Adverse Events section.

Participant flow — Overall Study
MilestoneJX-594 Intravenous InfusionJX-594 Intratumoral Injection
Started20
Completed00
Not completed20
Withdrew: Study termination by sponsor20

Outcome measures

SecondaryJX-594 Spread to, and Replication Within, Non-injected Tumors After IT JX-594 Injection

JX-594 spread to, and replication within, non-injected tumors after IT JX-594 injection as measured by the presence of viral protein expression and/or LacZ expression in non-injected tumor sections from at least 1) two different non-consecutive cuts, both of which contain viable tumor tissue in at least 10 high power fields; and 2) at least 5 cells in one high power field show positive staining for viral protein and/ or LacZ expression

Time frame:
Day 1

No measurements were reported for this outcome.

SecondaryModified Choi Response Assessment

Modified Choi response assessment based on DCE-MRI at baseline and between Days 8 14 (within 7 days prior to surgical resection)

Time frame:
Day 8-14

No measurements were reported for this outcome.

SecondaryToxicity: Grade I-IV Adverse Events (According to CTCAE)

Toxicity: Grade I-IV Adverse Events (according to CTCAE); including surgical complications such as delay of surgery, prolonged hospitalization, bleeding (monitor transfusion requirements), postoperative infections, bile leak, hepatic failure sepsis and death

Time frame:
Day 1- Day 43
Reported as:
Count of participants · Participants
Toxicity: Grade I-IV Adverse Events (According to CTCAE)
ParticipantsJX-594 Intravenous InfusionJX-594 Intratumoral Injection
Toxicity: Grade I-IV Adverse Events (According to CTCAE)2—
PrimaryDelivery to and Replication Within Tumors

IT injection: replication and dissemination of JX-594 following injection of a single colorectal metastasis within the liver. A positive replication response is defined as a \> 2-fold increase in viral genome concentration in the blood(as measured in the first 12 hours following injection) within the first 14 days following treatment. Note: Viral genomes will be measured in the blood by Q-PCR at baseline, on Day 1 (15 minutes, 3 hours \& 8 hours) post-treatment and on Days 3, 5, 8, 11 and 15. IV infusion: assessment of viral gene \& protein expression in histologic samples of tumor tissue

Time frame:
Day 1, 3, 5, 8, 11, and 15

No measurements were reported for this outcome.

Adverse events

Collected over From enrollment (Day 1) until early termination, up to 28 days after JX-594 treatment, for a total active study monitoring period of Day 1 through Day 43 per participant.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
JX-594 Intravenous Infusion0/2 (0%)1/2 (50%)2/2 (100%)
JX-594 Intratumoral Injection———
Most frequent serious events
Most frequent serious events
EventJX-594 Intravenous InfusionJX-594 Intratumoral Injection
Post procedural bile leakInjury, poisoning and procedural complications1/2—
Most frequent other events
Showing 10 of 18
Most frequent other events
EventJX-594 Intravenous InfusionJX-594 Intratumoral Injection
NauseaGastrointestinal disorders2/2—
VomitingGastrointestinal disorders2/2—
ChillsGeneral disorders2/2—
PyrexiaGeneral disorders2/2—
Decreased appetiteMetabolism and nutrition disorders2/2—
HeadacheNervous system disorders2/2—
MyalgiaMusculoskeletal and connective tissue disorders2/2—
DiarrhoeaGastrointestinal disorders1/2—
FatigueGeneral disorders1/2—
Mucosal infectionInfections and infestations1/2—

Baseline characteristics

The study was terminated early due to a sponsor decision. As a result, no participants reached the point of analysis for this outcome measure, and no data were collected or analyzed.

Age, Continuous
Age, Continuous(years)JX-594 Intravenous InfusionJX-594 Intratumoral InjectionTotal
Median53.5 (51 to 56)—53.5 (51 to 56)
Sex: Female, Male
Sex: Female, Male(Participants)JX-594 Intravenous InfusionJX-594 Intratumoral InjectionTotal
Female000
Male202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)JX-594 Intravenous InfusionJX-594 Intratumoral InjectionTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White202
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Ottawa Hospital and Research Institute (OHRI)
    Ottawa, Ontario K1H 8L6, Canada
09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jan 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2026, 14 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2011
First posted
Apr 6, 2011
Start
Oct 2011
Primary completionActual
Jan 2012
CompletionActual
Mar 2013
Results first posted
Oct 2, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Why stopped
Business decision by the sponsor
Oct 2, 2026
Results
Results posted
posted Oct 2, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedDelivery to and replication within tumorsReplication Within TumorsTime frame: Day 1, 3, 5, 8, 11, and 15
Oct 2, 2026
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedJX-594 spreadSpread to, and replication withinReplication Within, nonNon-injected tumors afterTumors After IT JX-594 injectionInjectionTime frame: Day 1
  • EditedModified Choi response assessmentResponse AssessmentTime frame: Day 8-14
  • EditedToxicity: Grade I-IV Adverse Events (accordingAccording to CTCAE)Time frame: Day 1- Day 43
Oct 2, 2026
Title
Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors→Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Why stopped Business decision by the sponsor
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedDelivery to and replication within tumorsReplication Within TumorsTime frame: Day 1, 3, 5, 8, 11, and 15
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedJX-594 spreadSpread to, and replication withinReplication Within, nonNon-injected tumors afterTumors After IT JX-594 injectionInjectionTime frame: Day 1
    • EditedModified Choi response assessmentResponse AssessmentTime frame: Day 8-14
    • EditedToxicity: Grade I-IV Adverse Events (accordingAccording to CTCAE)Time frame: Day 1- Day 43
    Title Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors→Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection
    + 3 other changes: index terms, verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01329809
Lead sponsor
Jennerex Biotherapeutics
Responsible party
Sponsor
First posted
Apr 6, 2011
Start date
Oct 2011
Primary completion
Jan 2012
Completion
Mar 2013
Results posted
Oct 2, 2026
Last update
Oct 2, 2026

Study contacts

Rebecca C Auer, MD
principal investigator · OHRI

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JX-594

Start the discussion